SARS-CoV-2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment

Sara Protić; Milica Crnoglavac Popović; Nevena Kaličanin; Olivera Prodanović; Milan Senćanski; Jelena Milićević; Kristina Stevanović; Vladimir Perović; Slobodan Paessler; Radivoje Prodanović; Sanja Glišić

doi:10.1002/open.202400091

SARS-CoV-2 PL^pro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment

Sara Protić, Milica Crnoglavac Popović, Nevena Kaličanin, Olivera Prodanović, Milan Senćanski, Jelena Milićević, Kristina Stevanović, Vladimir Perović, Slobodan Paessler, Radivoje Prodanović, Sanja Glišić

Pathology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The emergence of drug-resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID-19 pandemic. While de novo drug development is a time-consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS-CoV-2 papain-like protease inhibitor. This study extends those findings by investigating fidaxomicin‘s antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS-CoV-2, given its promising in vitro antiviral activity and favorable safety profile.

Original language	English (US)
Article number	e202400091
Journal	ChemistryOpen
Volume	13
Issue number	11
DOIs	https://doi.org/10.1002/open.202400091
State	Published - Nov 2024

Keywords

SARS-CoV-2 PLpro
antiviral therapy
drug repurposing
fidaxomicin
in vitro

ASJC Scopus subject areas

General Chemistry

Access to Document

10.1002/open.202400091

Cite this

Protić, S., Crnoglavac Popović, M., Kaličanin, N., Prodanović, O., Senćanski, M., Milićević, J., Stevanović, K., Perović, V., Paessler, S., Prodanović, R., & Glišić, S. (2024). SARS-CoV-2 PL^pro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment. ChemistryOpen, 13(11), Article e202400091. https://doi.org/10.1002/open.202400091

Protić, S, Crnoglavac Popović, M, Kaličanin, N, Prodanović, O, Senćanski, M, Milićević, J, Stevanović, K, Perović, V, Paessler, S, Prodanović, R & Glišić, S 2024, 'SARS-CoV-2 PL^pro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment', ChemistryOpen, vol. 13, no. 11, e202400091. https://doi.org/10.1002/open.202400091

@article{1a53b4d5893f4d2aa25916d9d6ae4deb,

title = "SARS-CoV-2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment",

abstract = "The emergence of drug-resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID-19 pandemic. While de novo drug development is a time-consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS-CoV-2 papain-like protease inhibitor. This study extends those findings by investigating fidaxomicin{\textquoteleft}s antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS-CoV-2, given its promising in vitro antiviral activity and favorable safety profile.",

keywords = "SARS-CoV-2 PLpro, antiviral therapy, drug repurposing, fidaxomicin, in vitro",

author = "Sara Proti{\'c} and \{Crnoglavac Popovi{\'c}\}, Milica and Nevena Kali{\v c}anin and Olivera Prodanovi{\'c} and Milan Sen{\'c}anski and Jelena Mili{\'c}evi{\'c} and Kristina Stevanovi{\'c} and Vladimir Perovi{\'c} and Slobodan Paessler and Radivoje Prodanovi{\'c} and Sanja Gli{\v s}i{\'c}",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. ChemistryOpen published by Wiley-VCH GmbH.",

year = "2024",

month = nov,

doi = "10.1002/open.202400091",

language = "English (US)",

volume = "13",

journal = "ChemistryOpen",

issn = "2191-1363",

publisher = "John Wiley \& Sons Inc.",

number = "11",

}

TY - JOUR

T1 - SARS-CoV-2 PLpro Inhibition

T2 - Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment

AU - Protić, Sara

AU - Crnoglavac Popović, Milica

AU - Kaličanin, Nevena

AU - Prodanović, Olivera

AU - Senćanski, Milan

AU - Milićević, Jelena

AU - Stevanović, Kristina

AU - Perović, Vladimir

AU - Paessler, Slobodan

AU - Prodanović, Radivoje

AU - Glišić, Sanja

PY - 2024/11

Y1 - 2024/11

N2 - The emergence of drug-resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID-19 pandemic. While de novo drug development is a time-consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS-CoV-2 papain-like protease inhibitor. This study extends those findings by investigating fidaxomicin‘s antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS-CoV-2, given its promising in vitro antiviral activity and favorable safety profile.

AB - The emergence of drug-resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID-19 pandemic. While de novo drug development is a time-consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS-CoV-2 papain-like protease inhibitor. This study extends those findings by investigating fidaxomicin‘s antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS-CoV-2, given its promising in vitro antiviral activity and favorable safety profile.

KW - SARS-CoV-2 PLpro

KW - antiviral therapy

KW - drug repurposing

KW - fidaxomicin

KW - in vitro

UR - https://www.scopus.com/pages/publications/85200208052

UR - https://www.scopus.com/inward/citedby.url?scp=85200208052&partnerID=8YFLogxK

U2 - 10.1002/open.202400091

DO - 10.1002/open.202400091

M3 - Article

C2 - 39099532

AN - SCOPUS:85200208052

SN - 2191-1363

VL - 13

JO - ChemistryOpen

JF - ChemistryOpen

IS - 11

M1 - e202400091

ER -